Meeting
2022 ASCO Annual Meeting
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1, and TIM-3 are markedly increased in basal cell carcinoma.
Authors
Bernardo Leon Rapoport
Department of Immunology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa
Bernardo Leon Rapoport , Nonkululeko Malinga , Shalete Siwele , Helen C. Steel , Luyanda LI Kwofie , Pieter Meyer , Teresa Smit , Ronald Anderson , Mahlatse Kgokolo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3043)
DOI
10.1200/JCO.2022.40.16_suppl.3043
Abstract #
3043
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Expression patterns of PD-L1 and other immune checkpoint molecules in gastric cancer.
First Author: Kenichi Nakamura
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Characterization of the cachexia pathway in pancreatic ductal adenocarcinoma.
First Author: Karam Ashouri
Poster
2023 ASCO Annual Meeting
Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma.
First Author: Bernardo Leon Rapoport
Poster
2023 ASCO Annual Meeting
Exploring the potential of combination immune checkpoint strategies in non-small cell lung cancer (NSCLC).
First Author: Aakash Desai